NCT04982549 2021-08-06A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCShandong Cancer Hospital and InstitutePhase 2 Unknown35 enrolled